SLC5A2 and type 2 diabetes mellitus: Similarly, sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as glucose-lowering drugs, have demonstrated significant cardiorenal benefits beyond T2D management [33,34,35,36,37,38,39,40,41,42,43].